Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: Implications for predictive testing

International Journal of Cancer

Volumn 122, Issue 8, 2008, Pages 1810-1819

  Almeida, Gabriela M ^a   Duarte, Tiago L ^a   Farmer, Peter B ^b   Steward, William P ^a   Jones, George D D ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cell cycle; Cisplatin; Comet assay; Gene expression; NSCLC

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG SENSITIVITY; DRUG TOLERANCE; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; CANCER STEM CELL; CELL PROLIFERATION; CROSS BREEDING; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LUNG TUMOR; PREDICTION AND FORECASTING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; COMET ASSAY; CROSS-LINKING REAGENTS; CROSSES, GENETIC; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC;

EID: 40349089783     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23188     Document Type: Article

References (51)

1. Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostickbruton F, Tarone R, Muggia FM. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 1993;53:3694-9.
2. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis 1988;9:1909-11.
3. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987;84:5024-8.
4. Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC, van Oosterom AT, Baan RA, Berends F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990;50:7887-94.
5. Parker RJ, Gill I, Tarone R, Vionnet JA, Grunberg S, Muggia FM, Reed E. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 1991;12:1253-8.
6. Schellens JHM, Ma J, Planting AST, Vanderburg MEL, Vanmeerten E, Deboerdennert M, Schmitz PIM, Stoter G, Verweij J. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 1996;73:1569-75.
7. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, Begg AC. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000;89:160-6.
8. Motzer RJ, Reed E, Perera F, Tang D, Shamkhani H, Poirier MC, Tsai WY, Parker RJ, Bosl GJ. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 1994;73:2843-52.
9. Fisch MJ, Howard KL, Einhorn LH, Sledge GW. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Clin Cancer Res 1996;2:1063-6.
10. Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin Cancer Res 1996;2:1829-35.
11. Peng B, Tilby MJ, English MW, Price L, Pearson ADJ, Boddy AV, Newell DR. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Br J Cancer 1997;76:1466-73.
12. Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, Pearson AD, Boddy AV, Newell DR, Tilby MJ. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clin Cancer Res 2001;7:2205-12.
13. Beadsmoore CJ, Screaton NJ. Classification, staging and prognosis of lung cancer. Eur J Radiol 2003;45:8-17.
14. Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, Minna JD, Gazdar AF. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res 1999;5:991-1000.
15. Le Chevalier T, Soria J-C. Status and trends of chemotherapy for advanced NSCLC. Eur J Cancer Supp 2004;2:26-33.
16. Almeida GM, Duarte TL, Steward WP, Jones GDD. Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair 2006;5:219-25.
17. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal-cells measured using the comet assay. Radiation Research 1990;122:86-94
18. Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999;5:507-12.
19. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002;100:224-9.
20. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001;98:31-6.
21. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
22. Rutledge RG, Cote C. Mathematics of quantitative kinetic PCR and the application of standard curves. Nucl Acids Res 2003;31:e93.
23. Vaisman A, Varchenko M, Said I, Chaney SG. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 1997;27:54-64.
24. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
25. Shellard S, Hosking L, Hill B. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Cancer Res 1991;51:4557-64.
26. Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtingerschepman AMJ, Shellard SA. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell-lines established from tumors from untreated patients. Eur J Cancer 1994;30A:832-7.
27. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JRW. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997;70:551-5.
28. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
29. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-25.
30. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
31. Sax JK, El-Deiry WS. Identification and Characterization of the Cytoplasmic Protein TRAF4 as a p53-regulated Proapoptotic Gene. J Biol Chem 2003;278:36435-44.
32. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
33. Nicholls CD, Shields MA, Lee PWK, Robbins SM, Beattie TL. UV-dependent alternative splicing uncouples p53 activity and PIG3 gene function through rapid proteolytic degradation. J Biol Chem 2004;279:24171-8.
34. Yakovlev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 2004;279:28367-74.
35. Hammerman PS, Fox CJ, Cinalli RM, Xu A, Wagner JD, Lindsten T, Thompson CB. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-{κ}B activation. Cancer Res 2004;64:8341-8.
36. El-Deiry WS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003;22:7486-95.
37. Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 1996;14:482-6.
38. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O'Connor PM, Appella E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependentámanner. Proc Natl Acad Sci USA 1997;94:6048-53.
39. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace AJJ, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002;31:210-15.
40. Nasmyth K. How do so few control so many? Cell 2005;120:739-46.
41. van Vugt MATM, Bras A, Medema RH. Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells. Mol Cell 2004;15:799-811.
42. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, Nakagawara A. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004;279:25549-61.
43. Wang G, Chuang L, Zhang X, Colton S, Dombkowski A, Reiners J, Diakiw A, Xu XS. The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation. Nucl Acids Res 2004;32:2231-40.
44. Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 2002;99:12985-90.
45. Tan T, Chu G. p53 binds and activates the Xeroderma Pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol 2002;22:3247-54.
46. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJJ, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
47. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, Damico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF. P53 gene-mutations in non-small-cell lung-cancer cell-lines and their correlation with the presence of Ras mutations and clinical-features. Oncogene 1992;7:171-80.
48. Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays 2000;22:728-37.
49. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002;32:180-4.
50. Hoffmann JS, Pillaire MJ, Garcia-Estefama D, Lapalu S, Villani G. In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic. J Biol Chem 1996;271:15386-92.
51. Vaisman A, Masutani C, Hanaoka F, Chaney SG. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 2000;39:4575-80.